[Relapse of chronic myeloid leukemia presenting with blurred vision after allogeneic hematopoietic stem cell transplantation].
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
unrelated bone marrow transplantation (BMT) for blast-phase chronic myeloid leukemia (CML)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Molecular remission was achieved on day 161 after relapse. Three years later, the patient remains in remission on dasatinib therapy.
A 34-year-old man underwent unrelated bone marrow transplantation (BMT) for blast-phase chronic myeloid leukemia (CML).
APA
Asano K, Kobayashi T, et al. (2026). [Relapse of chronic myeloid leukemia presenting with blurred vision after allogeneic hematopoietic stem cell transplantation].. [Rinsho ketsueki] The Japanese journal of clinical hematology, 67(1), 65-68. https://doi.org/10.11406/rinketsu.67.65
MLA
Asano K, et al.. "[Relapse of chronic myeloid leukemia presenting with blurred vision after allogeneic hematopoietic stem cell transplantation].." [Rinsho ketsueki] The Japanese journal of clinical hematology, vol. 67, no. 1, 2026, pp. 65-68.
PMID
41621967 ↗
Abstract 한글 요약
A 34-year-old man underwent unrelated bone marrow transplantation (BMT) for blast-phase chronic myeloid leukemia (CML). Molecular remission was achieved on day 29. Around day 600 after BMT, the patient developed blurred vision in the right eye. Peripheral blood major mRNA was undetectable on day 606. An ophthalmologic examination on day 613 identified circumferential iris thickening and anterior chamber hypopyon-like lesions in the right eye. Betamethasone and levofloxacin ophthalmic solutions were started on the same day. On day 624, the white lesion in the anterior chamber had resolved, but iris thickening persisted. On day 663, peripheral blood major BCR::ABL1 mRNA (IS) increased as well, and molecular relapse of CML was diagnosed. Dasatinib was started at 20 mg/day on day 6 after relapse, and blurred vision improved on day 10 after relapse. On day 27 after relapse, the white lesion in the anterior chamber and iris hyperplasia had also resolved. By day 147 after relapse, dasatinib was gradually increased to 100 mg/day. Molecular remission was achieved on day 161 after relapse. Three years later, the patient remains in remission on dasatinib therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.